International Working Group (IWG) 2 Criteria for Alzheimer's Disease Diagnosis
ورودیهای بالینی بیمار
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Typical ADtypical_ad–typical_ad
- Atypical ADatypical_ad–atypical_ad
- Mixed ADmixed_ad–mixed_ad
- Asymptomatic at Riskasymptomatic_at_risk–asymptomatic_at_risk
The International Working Group (IWG) 2 Criteria for Alzheimer's Disease Diagnosis calculates quantifying neurological deficit severity, stroke volume, and reperfusion therapy eligibility. Key inputs include clinical phenotype. Scores guide initiating intravenous thrombolysis, activating endovascular thrombectomy pathways, or secondary prevention protocols. Routine clinical application promotes standardized evidence-based patient management.
Clinical Guidelines & Evidence
Diagnoses Alzheimer's disease (AD) using revised research diagnostic criteria that integrate clinical phenotypes with pathophysiological biomarkers. The IWG-2 criteria represent a major advancement over previous diagnostic approaches by requiring both an appropriate clinical AD phenotype (typical or atypical) and pathophysiological biomarker evidence of Alzheimer pathology. This framework covers the full disease spectrum from asymptomatic at-risk individuals to typical and atypical AD presentations. The IWG-2 criteria distinguish between pathophysiological markers (CSF Aβ1-42, T-tau, P-tau, amyloid PET) used for diagnosis and topographical markers (volumetric MRI, FDG-PET) used for progression monitoring. This diagnostic tool enables earlier and more accurate identification of AD across the disease continuum, facilitating appropriate treatment planning and research enrollment.
Clinical Indication
The International Working Group (IWG) 2 Criteria for Alzheimer's Disease Diagnosis is indicated for bedside clinical practice to support Diagnoses Alzheimer's disease (AD) using revised research diagnostic criteria that integrate clinical phenotypes with pathophysiological biomarkers. The IWG-2 criteria represent a major advancement over previous diagnostic approaches by requiring both an appropriate clinical AD phenotype (typical or atypical) and pathophysiological biomarker evidence of Alzheimer pathology. This framework covers the full disease spectrum from asymptomatic at-risk individuals to typical and atypical AD presentations. The IWG-2 criteria distinguish between pathophysiological markers (CSF Aβ1-42, T-tau, P-tau, amyloid PET) used for diagnosis and topographical markers (volumetric MRI, FDG-PET) used for progression monitoring. This diagnostic tool enables earlier and more accurate identification of AD across the disease continuum, facilitating appropriate treatment planning and research enrollment.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with acute neurological deficits, acute ischemic stroke, intracranial hemorrhage, seizures, or altered mental status. Clinical application is indicated across Comprehensive stroke centers, acute neurovascular units, neuro-ICU, and emergency neurology services.
Limitations & Contraindications
Stroke mimics including severe hypoglycemia, Todd postictal paresis, and hemiplegic migraine must be ruled out prior to intravenous thrombolysis.
Clinical Pearls & Action Plan
Time is brain; rapid determination of Last Known Well time and baseline functional status dictates reperfusion eligibility.
Diagnosis requires: Clinical AD phenotype (typical/atypical/mixed) + Pathophysiological biomarker evidence (CSF Aβ1-42 ↓ and/or T-tau ↑ and/or P-tau ↑ and/or Amyloid PET +). Topographical markers (MRI, FDG-PET) used for progression monitoring only.
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| clinical_phenotype | string | Yes | Clinical presentation pattern of cognitive impairment |
| memory_impairment | string | Yes | Presence of episodic memory impairment (typical AD pattern) |
| cognitive_domains_affected | string | Yes | Number of cognitive domains significantly impaired |
| csf_amyloid_beta | string | Yes | CSF Aβ1-42 levels (pathophysiological biomarker)(pg/mL) |
| csf_tau | string | Yes | CSF total tau (T-tau) levels (pathophysiological biomarker)(pg/mL) |
| csf_ptau | string | Yes | CSF phosphorylated tau (P-tau) levels (pathophysiological biomarker)(pg/mL) |
| amyloid_pet | string | Yes | Amyloid PET imaging results (pathophysiological biomarker) |
| functional_decline | string | Yes | Progressive functional decline in activities of daily living |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| typical_ad–typical_ad | Typical AD | Meets criteria for typical Alzheimer's disease |
| atypical_ad–atypical_ad | Atypical AD | Meets criteria for atypical Alzheimer's disease |
| mixed_ad–mixed_ad | Mixed AD | Meets criteria for mixed Alzheimer's disease |
| asymptomatic_at_risk–asymptomatic_at_risk | Asymptomatic at Risk | Asymptomatic at risk for Alzheimer's disease |
| insufficient_criteria–insufficient_criteria | Insufficient Criteria | Does not meet IWG-2 criteria for AD diagnosis |
Evidence-Based References (EBM)
- Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol. 2014 Jun;13(6):614-29. doi: 10.1016/S1474-4422(14)70090-0.DOI: 10.1016/S1474-4422(14)70090-0
- Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018 Apr;14(4):535-562. doi: 10.1016/j.jalz.2018.02.018.DOI: 10.1016/j.jalz.2018.02.018
- Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S, et al. Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. Alzheimers Dement. 2016 Mar;12(3):292-323. doi: 10.1016/j.jalz.2016.02.002.DOI: 10.1016/j.jalz.2016.02.002